FinancialNewsMedia.com News Commentary

PALM BEACH, Fla., May 9, 2023 /PRNewswire/ -- Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which results in loss of memory, thinking and language skills, and behavioral changes. There is a rapid growth in the number of people living with Alzheimer's disease, and only around one in four people with the disease get diagnosed. A report from Mordor Intelligence projected that the Alzheimer's disease diagnostics and therapeutics market is expected to be valued at USD 9,639.23 million 2027, registering a growth with CAGR of 5.51% over the forecast period. The report said: "The major factors driving the growth of the Alzheimer's disease diagnostics and therapeutics market are the increasing use of biomarkers in Alzheimer's diagnosis and drug development and the rising prevalence of Alzheimer's worldwide. For instance, in September 2022, a report by the WHO stated that about 55 million people around the world are living with dementia, and nearly 10 million cases are reported annually. WHO also said that Alzheimer's is the most common form of dementia and constitutes about 60-70% of the total cases of dementia.  Also, with the growing prevalence of Alzheimer's around the world, government and non-government entities are investing heavily in developing diagnostics and therapeutics for the disease, which may augment the market's growth."  Active biotechs in the markets today include:   Silo Pharma, Inc. (NASDAQ: SILO), Eli Lilly and Company (NYSE: LLY), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Trevena, Inc. (NASDAQ: TRVN), Immuron Limited (NASDAQ: IMRN).